Novartis's Adakveo (crizanlizumab) Receives NICE Recommendation as a New Therapy for Sickle Cell Disease
Shots:
- The NICE has recommended Novartis’ Adakveo (crizanlizumab) as a new treatment option to prevent recurrent sickle cell crises in patients aged ≥16
- Additionally- patients will now have access to this treatment option on the NHS. The clinical evidence demonstrated that the people treated with crizanlizumab have significantly fewer sickle cell crises in a year compared to the other standard treatment options
- The recommendation was based on cost-effective treatment & the main objective of NICE is to reduce health inequalities. The therapy showed high uncertainty in the long-term & cost-effective treatment & will not be recommended for routine use on the NHS
Ref: NICE | Image: Novartis
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com